RESUMEN
OBJECTIVE: Timely dose reduction of concomitant medications is important after withdrawal of rifampicin, a CYP inducer. However, little is known about the differences in the time course of deinduction for various CYP isoforms. To clarify the time courses of deinduction of CYP2C9 and -CYP3A activities after rifampicin withdrawal, we monitored these enzyme activities in 2 patients over time after discontinuing rifampicin. MATERIALS AND METHODS: Two patients (aged 70 and 80 years) received warfarin and rifampicin for anticoagulation and antituberculosis therapy, respectively. Warfarin doses were increased due to rifampicin-induced CYP activity. Upon completion of antituberculosis therapy, rifampicin was discontinued and warfarin doses were titrated downward according to prothrombin time. We monitored CYP2C9 and CYP3A activities over their clinical courses by measuring the metabolic clearance of S-warfarin to S-7-hydroxywarfarin and that of cortisol to 6ß-hydroxycortisol, respectively. RESULTS: In both patients, the time courses of CYP2C9 deinduction appeared to be delayed compared to CYP3A. CONCLUSION: Our findings suggest that a uniform dose reduction protocol for drugs metabolized by different CYP isoforms may be unsafe after rifampicin withdrawal.â©.
Asunto(s)
Antibióticos Antituberculosos/efectos adversos , Anticoagulantes/administración & dosificación , Inductores del Citocromo P-450 CYP2C9/efectos adversos , Citocromo P-450 CYP2C9/biosíntesis , Inductores del Citocromo P-450 CYP3A/efectos adversos , Citocromo P-450 CYP3A/biosíntesis , Rifampin/efectos adversos , Warfarina/administración & dosificación , Anciano , Anciano de 80 o más Años , Antibióticos Antituberculosos/administración & dosificación , Anticoagulantes/efectos adversos , Anticoagulantes/farmacocinética , Coagulación Sanguínea/efectos de los fármacos , Inductores del Citocromo P-450 CYP2C9/administración & dosificación , Inductores del Citocromo P-450 CYP3A/administración & dosificación , Cálculo de Dosificación de Drogas , Interacciones Farmacológicas , Monitoreo de Drogas/métodos , Inducción Enzimática , Femenino , Humanos , Relación Normalizada Internacional , Polifarmacia , Tiempo de Protrombina , Rifampin/administración & dosificación , Especificidad por Sustrato , Warfarina/efectos adversos , Warfarina/farmacocinéticaRESUMEN
PURPOSE: To report the unsafe herb-drug interactions between a commercial product of noni juice and phenytoin in a human case. CASE REPORT: A 49-year-old-male has been treated with phenytoin for epilepsy for more than ten years. In spite of his medication adherence, persistent sub-therapeutic phenytoin levels, which were sometimes from low to undetectable, with the result of having poor seizure control were noted as the noni fruit juice was co-administered daily. The possible mechanism is speculated to be due to noni juiceinduced cytochrome P-450 2C9 metabolism of phenytoin. Owing to many beneficial effects of noni juice, the patient was unwilling to accept our advice to quit taking it. Clobazam treatment was added, and with gradually reducing the amount of juice drunk over six months, the patient's epilepsy has been well controlled. Now only auras along with sometimes minor partial seizures occur, but no major attack has been reported for more than one year. CONCLUSION: Phenytoin had been commonly used for seizure control worldwide and nearly half of patients with epilepsy had received complementary and alternative medicine in Taiwan. Thus, this report is significantly important for clinicians to be aware of the interaction between antiepileptic drugs and some herbs like noni juice. Moreover, as far as we know, this is a rare human case that is reported to disclose this unfavorable herb-drug interaction.
